Miranda Jayne Toledano
Miranda Jayne Toledano's purchase track record
How the stock did after each of Miranda Jayne Toledano's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/29/2025 | ENTX | $20K | -44.4% | -8.3% | +7.7% |
| 12/22/2023 | ENTX | $17K | +143.1% | +210.8% | +14.9% |
| 4/4/2023 | ENTX | $30K | -10.2% | -26.5% | +3.1% |
| 11/11/2022 | ENTX | $27K | +82.0% | +88.0% | +3.3% |
| 1/14/2022 | ENTX | $19K | -2.1% | -50.5% | -17.2% |
| 12/27/2021 | NXGL | $10K | -40.0% | -42.5% | -18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Options Activity Signals Possible Move in Journey Medical (DERM). Options traders are increasing positions in Journey Medical, hinting at a potential price move. The stock is near its 9‑touch support level of $6.05 and has recently touched the 200‑day SMA, adding to the technical backdrop. Analysts currently target a range of $13.00 to $15.00, well above the 52‑week high of $9.55.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
NXGL Listed Among 12 Health Care Stocks Moving in Pre‑Market Session. NXGL was one of 12 health‑care stocks that moved in Wednesday’s pre‑market session. The move reflects short‑term interest in the sector. The stock is trading near its 52‑week low and has a low RSI, which may have contributed to the pre‑market activity.
Transaction History
| ENTX | ▲ Buy | Grant | 347,567 | $0 | 7/14/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 72,993 | $0 | 7/14/2026 | View on chart |
| DERM | ▲ Buy | Grant | 50,000 | $0 | 7/1/2026 | View on chart |
| DERM | ▲ Buy | Grant | 10,000 | $0 | 6/25/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 11,000 | $20K | 12/29/2025 | View on chart |
| DERM | ▲ Buy | Grant | 20,000 | $0 | 8/5/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 136,842 | $0 | 7/16/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 43,860 | $0 | 7/16/2025 | View on chart |
| DERM | ▲ Buy | Grant | 7,173 | $0 | 6/25/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 124,121 | $0 | 7/31/2024 | View on chart |
| DERM | ▲ Buy | Grant | 9,728 | $0 | 7/8/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 23,952 | $17K | 12/22/2023 | View on chart |
| DERM | ▲ Buy | Grant | 27,472 | $0 | 7/21/2023 | View on chart |
| ENTX | ▲ Buy | Open Market | 30,000 | $30K | 4/4/2023 | View on chart |
| ENTX | ▲ Buy | Open Market | 50,000 | $27K | 11/11/2022 | View on chart |
| DERM | ▲ Buy | Grant | 14,245 | $0 | 7/21/2022 | View on chart |
| DERM | ▲ Buy | Grant | 30,000 | $0 | 1/14/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 6,800 | $19K | 1/14/2022 | View on chart |
| NXGL | ▲ Buy | Open Market | 1,819 | $10K | 12/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.